What happens to InMode device pricing if Steel Partners wins the takeover?

Pricing typically shifts during ownership transitions as new operators reassess margins and market positioning. Steel Partners' lack of prior aesthetic-device experience means they may either maintain current pricing or restructure rebate and warranty terms to improve profitability—practice owners should lock in pricing agreements now if possible.

Will InMode RF microneedling devices still be supported after a Steel Partners acquisition?

Support continuity is uncertain under new ownership. Steel Partners is a diversified industrial investor without aesthetic-device operating experience, so training, warranty, and technical support structures could remain stable or undergo significant restructuring depending on their operational strategy.

Should I buy an InMode device now before the takeover closes?

If you're considering purchase, now is a strategic time to negotiate—uncertainty often creates leverage for buyers seeking locked-in pricing, extended warranties, or favorable rebate terms. Contact your InMode rep to discuss transition protections before ownership changes hands.

What is Steel Partners' track record with medical device companies?

Steel Partners is a diversified industrial investor with no prior operating experience in aesthetic or medical devices, making this acquisition a new category for them. Their hands-off or restructuring approach will likely depend on InMode's profitability and market position post-acquisition.

How long will the InMode takeover battle take to resolve?

The article does not specify a timeline, but contested takeovers typically take 3-6 months to resolve through shareholder votes and regulatory approval. Practice owners should monitor official InMode communications for updates on the bid process and expected closing date.

What other aesthetic device companies might be affected by InMode consolidation?

The article indicates device consolidation is accelerating across the aesthetic space, though specific competitors are not named. This suggests RF and energy-device manufacturers may face similar acquisition pressure, potentially affecting pricing and availability across the market.

Monday, August 24, 2026 Never miss a recall or a rule change Go Pro · $20/mo →

RegulatoryAbbVie Launches Phase 2 Forehead Lines Studytoday MarketFacial Rejuvenation Market Forecast to Hit $5.66B by 20302 days ago Business & M&AAllergan Aesthetics Overhauls Loyalty Programtoday Devices & TechXERF Technology Enters Australian Market for Skin Tightening2 days ago Business & M&AEvolus Expands Estyme to Canada, Australia, New Zealandtoday MarketArm Fat Now Top Body Sculpting Concern in Singapore2 days ago Devices & TechSofwave Hits One Million Treatments Milestonetoday RegulatoryCKD Bio Pursues China Botox Approval—2027 Launch Targeted2 days ago RegulatoryRevance Wins FDA Nod for Under-Eye Injectablesyesterday MarketGLP-1 Pill Era Is Forcing Beauty Market Shiftyesterday InjectablesAEON Releases Expanded ABP-450 Botox Biosimilar Datayesterday Devices & TechUltherapy PRIME Real-Time Imaging Reshapes Midface Liftingyesterday

Business & M&A

Steel Partners Bids $16.75/Share for InMode — What a Contested Takeover Means for Device Buyers

Unsolicited offer challenges CEO-led buyout; device consolidation accelerates.

By Evan at Inside MedSpa · Jul 11, 2026

1-YEAR MOVE

INMD ▲1.0%

1-year price move by ticker
Ticker	Company	1-year change
INMD	InMode Ltd.	+1.0%

Steel Partners, already a significant InMode shareholder, has made an unsolicited $16.75-per-share cash offer to acquire the RF microneedling and energy-device manufacturer, topping a competing CEO-led buyout proposal. The move signals aggressive consolidation in the aesthetic-device space and raises questions about InMode's strategic direction and product roadmap under new ownership.

Inside MedSpa Pro

You've reached your free articles this week.

Keep reading every article, unlock the full trackers, and get the twice-a-week intelligence brief — from $20/mo, or $200/yr (two months free). Never miss a recall or a rule change.

Every article, unlocked — no weekly limit
The full 50-state law tracker, stock & M&A watch
The twice-a-week, 2-minute intelligence brief
Recalls, FDA clearances & safety signals as they hit

See everything you get →

Cancel anytime, one click · 14-day money-back on annual

https://insidemedspa.com/article/steel-partners-inmode-acquisition-bid-16-75-per-share/

Discussion

Free alerts

Get flagged before it costs you.

We'll flag the moment a recall or rule change hits your practice. One email a week, one click to leave.

Free · weekly · unsubscribe anytime. Privacy.

This morning's brief · 6 AM

The free version stops here.

What today's moves mean for your margins — and exactly what to do — already went out to Pro. By the time the trade press explains it, the window to act has closed.

Go Pro · $20/mo Two minutes a morning. Cancel anytime.

Live · Market movers

STRATA Skin Sciences-50%Hims & Hers Health+6.03%Estée Lauder+6.02%Bausch Health (Solta)-5.43%The Beauty Health Company (HydraFacial)+3.65%

The full stock & M&A watch →

FDA Activity — Aesthetic Devices

Monthly 510(k) clearances vs. recalls.

510(k) clearances Recalls

FDA Activity — Aesthetic Devices — Monthly 510(k) clearances vs. recalls.
Month	510(k) clearances	Recalls
Jun '25	0	4
Jul '25	0	1
Sep '25	0	1
Oct '25	0	2
Jan '26	0	1
Feb '26	0	5
Mar '26	0	5
Apr '26	0	19
May '26	7	18
Jun '26	34	8
Jul '26	23	4
Aug '26	5	0

The 50-state regulation tracker →

Inside MedSpa Pro

By the time it's news, it's too late.

The rebate cut, the scope-of-practice bill, the competitor opening down the street — it hits your business before the trade press ever covers it. Pro gets you there first: what happened, why it touches your margins, and exactly what to do — at 6 AM, in two minutes.

Go Pro · $20/mo Never miss a recall or a rule change. Cancel anytime.

The twice-a-week intelligence brief Go Pro · $20/mo →

Steel Partners Bids $16.75/Share for InMode — What a Contested Takeover Means for Device Buyers

Share

Discussion

Leave a comment

By the time it's news, it's too late.